Loading data for TLSA — first visit, this takes a few seconds.

Tiziana Life Sciences Ltd (TLSA)

NasdaqCM: TLSA · 实时价格 · USD

0.96

+0.00 (0.00%)

收盘价： Sep 11, 2026, 3:59 PM

1.00

+3.85%

盘后: 7:30 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

-0.41% (1D)

买价	0.97
市值	122M
营收（TTM）	n/a
净利润（TTM）	-18.4M
	0.45
	-0.16
	n/a
	-4.81
市净率（TTM）	0.00
市销率（TTM）	0.00
财报日期	n/a

卖价	0.99
成交量	272,913
20日均量	576,601
开盘价	0.98
前收盘价	0.96
日内区间	0.93 - 0.99
52周区间	0.87 - 2.35
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 TLSA

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic latera...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Nov 20, 2018

员工人数 10

交易所 NasdaqCM

股票代码 TLSA

官网 https://www.tizianalifesciences.com

公司完整简介

财务表现

2025年，Tiziana Life Sciences Ltd的营收为0，较上一年的0增长undefined%。净利润为-18.43M，增长55.37%。

财务报表

财报意外

Tiziana Life Sciences Ltd 已于 Dec 27, 2022 发布季度财报：

营收为 n/a 低于预期 $0, ， NaN% 同比增长.
每股收益为 -0.06 低于预期 , ， -Infinity% 同比下滑.

股价变动原因

新闻

1周前 · Proactive

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potentia...

2周前 · Proactive

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The pres...

2周前 · Proactive

Wall Street ends on a mixed note as Dow gains despite semiconductor slump

Trade tensions, bond yields, Jackson Hole and a heavyweight earnings slate are all competing for attention

1月前 · Proactive

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal fo...

2月前 · Proactive

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Mul...

第 1 页，共 2 页

Tiziana Life Sciences Ltd (TLSA)